HSBC Upgrades Teva Pharmaceutical (TEVA) to Overweight
More News related to TEVA
- AstraZeneca (AZN) Settles Infringement Suit with Teva (TEVA) Subsidiary; Confirms FY09 EPS Outlook
- Teva Pharmaceuticals USA (TEVA) Signs Agreement to Settle Patent Litigation with AstraZeneca (AZN)
- Teva Announces Agreement on Generic Pulmicort Respules(R) Patent Challenge
- Watson Pharmaceuticals (WPI) Agrees to Acquire Portfolio of Generic Pharma Products Following Teva/Barr Merger
- Barr (BRL) Shareholders Approval Proposed Acquisition of Teva (TEVA)
HSBC upgrades Teva Pharmaceutical (Nasdaq: TEVA) from Neutral to Overweight.
Teva Pharmaceutical Industries Ltd. is a Global pharmaceutical company that develops, produces and markets generic drugs covering all major treatment categories.
Related Categories
UpgradesStocks Mentioned
-1.41Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
